Worldwide Clinical inks partnership deal with Deep Lens

Worldwide Clinical Trials inked a partnership deal with digital pathology startup Deep Lens to focus on the field of oncology. (Pixabay)

Global CRO Worldwide Clinical Trials has inked a partnership deal with digital pathology startup Deep Lens to focus on the field of oncology.

The partnership is designed to support sponsors, researchers and care teams to accelerate cancer diagnoses and provide improved treatment and clinical trial options earlier on in the process, the companies said in a release. Financial terms of the deal weren’t disclosed.

Worldwide and Deep Lens said they will develop a pilot study to mesh innovative clinical trial designs and operational knowledge with Deep Lens’ Virtual Imaging for Pathology Education and Research (VIPER) digital pathology platform that was originally developed at the Nationwide Children’s Hospital in Columbus, Ohio.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The VIPER system not only scans and digitizes glass slides used in research, it also figures out how to present those images and supporting information to pathologists in a way that streamlines their workflow, facilitates case review, and supports clinical and translational research.

RELATED: Digital pathology startup Deep Lens launches with $3.2M

“We need to up our game as pathologists and CROs to deliver increased precision, speed and communication to find patients with particular disease subtypes or biomarkers,” Dave Billiter, co-founder and chief executive of Deep Lens, said in a statement. “With the global reach and scientific and operations expertise of Worldwide, we believe we can streamline clinical trial recruitment. And, just as importantly, oncologists can inform patients and their caregivers about clinical research options from day one.”

Deep Lens launched in October with $3.2 million in funding.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.